“Researchers at the George Washington University School of Medicine and Health Sciences in partnership with Baylor College of Medicine report encouraging results from a phase 2 clinical trial evaluating a candidate vaccine to prevent hookworm infection – one of the world’s most common parasitic diseases.
The findings, published in The Lancet Infectious Diseases, show that a formulation of the investigational vaccine significantly reduced the intensity of infection in healthy adult volunteers exposed to the parasite under carefully controlled conditions…
- Participants who received the Na-GST 1/Al–CpG vaccine showed a dramatically lower intensity of infection after exposure: maximal hookworm egg count was median 0.0 eggs per gram of feces compared with the placebo group (median 66.7 eggs)
- Peak eosinophil levels – a blood marker linked to parasitic infection – were significantly lower in the Na-GST-1/Al–CpG group of participants.
- This group of participants also produced the highest levels of anti–Na-GST-1 antibodies, suggesting these antibodies may help protect against infection.”
From Newswise.
